Ray Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ray Therapeutics, Inc. - overview
Established
2021
Location
Berkeley, CA, US
Primary Industry
Biotechnology
About
Founded in 2021 and based in CA, US, Ray Therapeutics, Inc is a biotech company developing optogenetic gene therapies for patients with blinding diseases. Paul Bresge is the CEO of the company. In April 2026, Ray Therapeutics, Inc. raised USD 125 million in series B funding led by Janus Henderson Investors, with participation from Adage Capital Management, Franklin Templeton, Invus Financial Advisors, Marshall Wace, 4BIO Capital Partners, Deerfield Management, MRL Ventures Fund, Norwest Venture Partners, Novo Holdings, and Platanus Ventures.
The company's lead candidate Ray-001 in retinitis pigmentosa, a degenerative retinal disease with significant unmet medical needs. Ray-001 is intended to be a one-time treatment via intravitreal injection that is sustainable for a lifetime. The firm pursues multiple drug development programs for a range of degenerative retinal diseases, focusing on preserving and restoring vision in patients using the ground-breaking science of optogenetics. The company will use the April 2026 funding to support late-stage clinical development and commercial readiness for its lead program RTx-015 in retinitis pigmentosa and to advance clinical studies for RTx-021 in Stargardt disease and geographic atrophy.
Current Investors
4BIO Capital Partners, California Institute for Regenerative Medicine, Norwest Venture Partners
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Optometrists & Opticians Products and Services
Website
www.raytherapeutics.com
Company Stage
Series B
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.